Listed as a "Preferred Drug" by Two of the Three Major PBMs in the U.S. After Launch

Celltrion is accelerating its push into the North American market by securing additional approval in Canada for the autoinjector (AI) formulation of its ustekinumab biosimilar, Stekima. With this latest development, Celltrion has established a "full lineup" in Canada, offering all available formulations, which, combined with its prescription base in the United States, is seen as a concrete step forward in its market expansion strategy.

Celltrion Corporate Logo Image. Celltrion

Celltrion Corporate Logo Image. Celltrion

View original image

On March 20, Celltrion announced that it had received product approval for the Stekima autoinjector formulation from Health Canada. This approval adds two self-injectable options, 45mg and 90mg, to its portfolio. In addition to the existing intravenous and subcutaneous formulations, patients can now choose a self-administration option, completing Celltrion’s formulation portfolio.


Securing the autoinjector formulation, which the original drug does not offer, is highlighted as a key differentiator. Amid growing demand for self-injectable medications, this structure improves both convenience and accessibility for patients. It is expected to be especially beneficial for patients who find frequent visits to healthcare facilities challenging.


The company’s strategy to expand in the North American market is also becoming more visible. Since its launch in the United States, Stekima has been listed as a preferred product in the formularies of two out of the three major pharmacy benefit managers. By securing insurance coverage, Celltrion is increasing prescription accessibility and accelerating its market penetration.


In fact, Celltrion’s market share in the U.S. has been rising rapidly. As of January this year, it recorded an approximately 8.6% share in the ustekinumab market. Despite being in the early stages of entry, the product is said to be spreading at a relatively fast pace.


The market environment itself is also shifting in favor of biosimilars. Globally, the ustekinumab market is transitioning from being dominated by the original product to a biosimilar-centered structure. According to the company, sales of the original drug have decreased from around 30 trillion won to the 10 trillion won range within a year.


Celltrion is expanding its influence across the entire autoimmune disease treatment segment, broadening its portfolio from TNF-alpha inhibitors to include interleukin inhibitors. The company aims to further increase prescriptions through synergy with its existing product lineup established in Canada.



A Celltrion representative stated, "With this approval, we have secured a differentiated administration option in Canada that the original product does not offer, further solidifying Stekima’s position. Leveraging proven product competitiveness and the full lineup synergy across North America, we will take the lead in the global ustekinumab market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing